Modella AI vs Nucleai (2026)
Both sell AI for pathology research rather than clinical diagnosis. Modella's PathChat 2 is a generative copilot for research and education, and AstraZeneca has acquired Modella and is integrating the platform into its oncology research and development. Nucleai delivers expert led tissue analysis for drug developers, linking features in H&E, immunohistochemistry, multiplex and spatial data to clinical outcomes, with work across more than 12 clinical trials and a collaboration with Gilead on its ADC programs.
- You want a conversational copilot for pathology research or teaching, usable from a microscope, viewer or phone.
- You work with AstraZeneca's oncology research.
- You want an agent that automates AI model development on biomedical images, which Judith does.
- You run biopharma trials and want tissue features linked to clinical outcomes.
- Your data includes multiplex imaging or spatial transcriptomics.
- You want the analysis delivered by the vendor's experts rather than run yourself.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Modella AI and Nucleai are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Modella AI | Nucleai |
|---|---|---|
| Primary category | Digital Pathology AI | Digital Pathology AI |
| Founded | 2023 | 2016 |
| Headquarters | Boston, Massachusetts, United States | Tel Aviv, Israel |
| Website | modella.ai | nucleai.ai |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Boston biomedical AI company, acquired by AstraZeneca, building generative and agentic tools for pathology. PathChat combines pathology foundation models pretrained on histology image and image text data with a custom trained multimodal large language model, and PathChat 2 is offered as a copilot for research and education that can be used from a microscope, a slide viewer or a smartphone; Judith is an agent for automating AI model development on biomedical images.
Source: AI Health Index, September 2026
Tissue intelligence company for drug development, applying computer vision and machine learning to H&E, immunohistochemistry, multiplex imaging and spatial transcriptomics and linking tissue features to clinical outcomes. Delivered as expert led analysis for biopharma translational, biomarker and translational pathology teams, including an ongoing collaboration with Gilead on its ADC clinical programs, with work across more than 12 clinical trials and 30 indications.
Source: AI Health Index, September 2026
Questions buyers ask
How are Modella AI and Nucleai priced and sold?
For Modella AI, the company is venture backed and private, so there is no listing driven financial disclosure either.
With Nucleai, the commercial model appears to combine pharmaceutical partnership agreements with platform access, and neither structure nor economics are disclosed. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
How do Modella AI and Nucleai handle patient data?
In Modella AI's case, the site states no retention period, deidentification practice or training use for images submitted to PathChat, though the privacy policy may address them.
The user terms (31 March 2026) say Nucleai may use users' input and content to further develop, improve and enhance the solution, including through machine learning, subject to any customer services agreement. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
What evidence is published for Modella AI and Nucleai?
With Modella AI, the company links the Nature (2024) paper describing PathChat and its evaluation on pathology diagnostic questions against other multimodal models, and Nature Biotechnology work on the underlying foundation models, from the Mahmood Lab at Mass General Brigham.
In Nucleai's case, a health system has explored the technology as a treatment decision tool in real world care. What does not yet exist publicly is prospective validation that spatial biomarkers derived by the platform improve treatment selection outcomes. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Digital Pathology AI page.
Neither makes a device claim for these products; Modella's diagnostic version holds a Breakthrough Device Designation, which is not an authorization. Rewritten 28 Sep 2026 after both records were reviewed.